Next Article in Journal
Innate Type 2 Responses to Respiratory Syncytial Virus Infection
Previous Article in Journal
Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development
Previous Article in Special Issue
Transcutaneous Administration of Dengue Vaccines
Open AccessReview

The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines

Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(5), 520; https://doi.org/10.3390/v12050520
Received: 21 April 2020 / Revised: 5 May 2020 / Accepted: 6 May 2020 / Published: 8 May 2020
(This article belongs to the Special Issue Flavivirus Vaccines)
Live-attenuated vaccines (LAVs) have achieved remarkable successes in controlling virus spread, as well as for other applications such as cancer immunotherapy. However, with rapid increases in international travel, globalization, geographic spread of viral vectors, and widespread use of vaccines, there is an increasing need to consider how pre-exposure to viruses which share similar antigenic regions can impact vaccine efficacy. Pre-existing antibodies, derived from either from maternal–fetal transmission, or by previous infection or vaccination, have been demonstrated to interfere with vaccine immunogenicity of measles, adenovirus, and influenza LAVs. Immune interference of LAVs can be caused by the formation of virus–antibody complexes that neutralize virus infection in antigen-presenting cells, or by the cross-linking of the B-cell receptor with the inhibitory receptor, FcγRIIB. On the other hand, pre-existing antibodies can augment flaviviral LAV efficacy such as that of dengue and yellow fever virus, especially when pre-existing antibodies are present at sub-neutralizing levels. The increased vaccine immunogenicity can be facilitated by antibody-dependent enhancement of virus infection, enhancing virus uptake in antigen-presenting cells, and robust induction of innate immune responses that promote vaccine immunogenicity. This review examines the literature on this topic and examines the circumstances where pre-existing antibodies can inhibit or enhance LAV efficacy. A better knowledge of the underlying mechanisms involved could allow us to better manage immunization in seropositive individuals and even identify possibilities that could allow us to exploit pre-existing antibodies to boost vaccine-induced responses for improved vaccine efficacy. View Full-Text
Keywords: live-attenuated vaccine; vaccine immunogenicity; antibody-dependent enhancement; vaccine immune interference; pre-existing antibodies live-attenuated vaccine; vaccine immunogenicity; antibody-dependent enhancement; vaccine immune interference; pre-existing antibodies
Show Figures

Graphical abstract

MDPI and ACS Style

Mok, D.Z.L.; Chan, K.R. The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines. Viruses 2020, 12, 520.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop